Aurobindo Hyderabad plant in regulatory trouble, share price falls 8%

The US Food and Drug Administration issued Form 483 with 14 observations to the company following the completion of inspection from November 4-14.

Aurobindo Pharma Limited scrip fell more than 8 per cent on Bombay Stock Exchange on Thursday reacting to the latest adverse inspectional outcome at the company's Unit 4, Injectable formulations facility at Pashamylaram in Hyderabad.

The US Food and Drug Administration (USFDA) issued Form 483 with 14 observations to the company following the completion of inspection from November 4-14.

This is Aurobindo's third facility to receive critical observations from the US drug regulator in this month and the sixth facility that failed to pass the US FDA inspection since June this year. The company was issued a Warning Letter for one of